Antiproliferative effect of the somatostatin analogue octreotide on growth hormone-producing pituitary tumors: Results of a multicenter randomized trial

Mayo Clinic Proceedings

Volumn 72, Issue 10, 1997, Pages 893-900

  Thapar, Kamal ^a   Kovacs, Kalman T ^b   Stefaneanu, Lucia ^c   Scheithauer, Bernd W ^d   Horvath, Eva ^b   Lloyd, Ricardo V ^a   Li, Joseph ^b   Laws Jr , Edward R ^c  

^a Department of Surgery   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c MAYO CLINIC ROCHESTER   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67; OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GROWTH HORMONE RELEASE; HUMAN; HYPOPHYSIS ADENOMA; IMMUNOPHENOTYPING; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030856814     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-6196(11)63358-2     Document Type: Article

References (35)

1. Lamberts SW, Verleun T, Oosterom R. The interrelationship between the effects of somatostatin and human pancreatic growth hormone-releasing factor on growth hormone release by cultured pituitary tumor cells from patients with acromegaly. J Clin Endocrinol Metab 1984;58:250-254
2. Sassolas G. Medical therapy with somatostatin analogues for acromegaly. Eur J Endocrinol 1995;133:675-677
3. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996;334:246-254
4. Ezzat S, Snyder PJ, Young WE, Boyajy LD, Newman C, Klibanski A, et al. Octreotide treatment of acromegaly: a randomized, multicenter study. Ann Intern Med 1992; 117:711-718
5. Newman CB, Melmed S, Snyder PJ, Young WE, Boyajy LD, Levy R, et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients-a clinical research center study. J Clin Endocrinol Metab 1995;80:2768-2775
6. Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide: results of the International Multicenter Acromegaly Study Group. Arch Intern Med 1991 ;151:1573-1578
7. Lamberts SW. Reubi JC, Krenning EP. Somatostatin analogs in the treatment of acromegaly. Endocrinol Metab Clin North Am 1992Sep;21:737-752
8. Barkan AL, Lloyd RV, Chandler WE, Hatfield MK, Gebarski SS, Kelch RP, et al. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrink-age of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 1988;67:10401048
9. Ezzat S, Horvath E, Harris AG, Kovacs K. Morphological effects of octreotide on growth hormone-producing pituitary adenomas. J Clin Endocrinol Metab 1994;79:113-118
10. George SR, Kovacs K, Asa SL, Horvath E, Cross EG, Burrow GN. Effect of SMS 201-995, a long-acting somatostatin analogue, on the secretion and morphology of a pituitary growth hormone cell adenoma. Clin Endocrinol 1987; 26:395-405
11. Cheung NW, Boyages SC. Somatostatin-14 and its analog octreotide exert a cytostatic effect on GH3 rat pituitary tumor cell proliferation via a transient GO/G1 cell cycle block. Endocrinology 1995;136:4174-4181
12. Ezzat S, Kontogeorgos G, Redelmeier DA, Horvath E, Harris AG, Kovacs K. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. Eur J Endocrinol 1995;133:686-690
13. Cattoretti G, Becker MH, Key G, Duchrow M, Schluter C, Galle J, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992; 168:357-363
14. Gerdes J. Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. Semin Cancer Biol 1990; 1:199-206
15. Taylor CR, Shi SR, Chaiwun B, Young L, Imam SA, Cote RJ. Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen, and Ki-67 antigen revealed by antigen retrieval techniques. Hum Pathol 1994;25:263-270
16. Thapar K, Kovacs K, Scheithauer B, Stefaneanu L, Horvath E, Pernicone PJ, et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 1996;38:99-106
17. Hsu SM, Raine L, Fanger H. The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics. Am J Clin Pathol 1981;75:816-821
18. Fahlbusch R, Honegger J, Buchfelder M. Surgical management of acromegaly. Endocrinol Metab Clin North Am 1992 Sep;21:669-692
19. Davis DH, Laws ER Jr, Ilstrup DM, Speed JK, Caruso M, Shaw EG, et al. Results of surgical treatment for growth hormone-secreting pituitary adenomas. J Neurosurg 1993; 79:70-75
20. Thapar K, Kovacs K, Muller PJ. Clinical-pathological correlations of pituitary tumours. Baillieres Clin Endocrinol Metab 1995;9:243-270
21. Todisco A, Campbell V, Dickinson CJ, DelValle J, Yamada T. Molecular basis for somatostatin action: inhibition of c-fos expression and AP-1 binding. Am J Physiol 1994; 267:G245-G253
22. Todisco A, Seva C, Takeuchi Y, Dickinson CJ, Yamada T. Somatostatin inhibits AP-1 function via multiple protein phosphatases. Am J Physiol 1995;269:G160-G166
23. Srikant CB. Cell cycle dependent induction of apoptosis by somatostatin analog SMS 201-995 in AtT-20 mouse pituitary cells. Biochem Biophys Res Commun 1995;209:400-406
24. Knosp E, Kitz K, Perneczky A. Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery 1989;25:927-930
25. Pines J. Cyclins, CKDs and cancer. Semin Cancer Biol 1995;6:63-72
26. Reubi JC, Laissue JA. Multiple actions of somatostatin in neoplastic disease. Trends Pharmacol Sei 1995; 16:110-115
27. Pinski J, Halmos G, Yano T, Szepeshazi K, Qin Y, Ertl T, et al. Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrinreleasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160. IntJ Cancer 1994;57:574-580
28. LeRiche VK, Asa SL, Ezzat S. Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness. J Clin Endocrinol Metab 1996;81:656-662
29. Reubi JC, Schaer JC, Laissue JA, Waser B. Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. Metabolism 1996;45(Suppl):39-41
30. Hoyer D, Bell GI, Berelowitx M, Epelbaum J, Feniuk W, Humphrey PP, et al. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sei 1995; 16:8688
31. Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT, Klibanski A. Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab 1995;80:1386-1392
32. Greenman Y, Melmed S. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 1994;79:724-729
33. Greenman Y, Melmed S. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab 1994;78:398-403
34. Buscail L, Esteve JP, Saint-Laurent N, Bertrand V, Reisine T, O'Carroll AM, et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sei U S A 1995;92:15801584
35. Tindall GT, Kovacs K, Horvath E, Thorner MO. Human prolactin-producing pituitary adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab 1982;55:11781183